Literature DB >> 18341960

Transcatheter arterial embolization with absolute ethanol injection for enlarged polycystic kidneys after failed metallic coil embolization.

Yusuke Sakuhara1, Fumi Kato, Daisuke Abo, Yu Hasegawa, Tadashi Shimizu, Satoshi Terae, Hiroki Shirato.   

Abstract

Kidney enlargement in autosomal-dominant polycystic kidney disease (ADPKD) may cause symptoms by compressing the alimentary tract, lungs, and heart. The clinical symptoms may be progressive, may markedly decrease quality of life, and may even be life-threatening. Although treatment of this disease is often difficult, transcatheter arterial embolization (TAE) with metallic coils has been reported as a renal contraction therapy that is less invasive than surgery. The present report describes a case of ADPKD successfully treated by TAE with absolute ethanol after a previous TAE procedure with metallic coils failed to contract the affected kidneys because of recanalization.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18341960     DOI: 10.1016/j.jvir.2007.10.007

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  11 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 2.  Evaluation and management of pain in autosomal dominant polycystic kidney disease.

Authors:  Marie C Hogan; Suzanne M Norby
Journal:  Adv Chronic Kidney Dis       Date:  2010-05       Impact factor: 3.620

3.  Usefulness of portography and contrast-enhanced computed tomography to predict the embolized area in percutaneous transhepatic portal vein embolization with absolute ethanol under temporary balloon occlusion.

Authors:  Yu Hasegawa; Daisuke Abo; Yusuke Sakuhara; Fumi Kato; Tamotsu Kamishimma; Tadashi Shimizu; Yoichi M Ito; Satoshi Terae; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2011-12-02       Impact factor: 2.374

4.  Suitability of Patients with Autosomal Dominant Polycystic Kidney Disease for Renal Transcatheter Arterial Embolization.

Authors:  Tatsuya Suwabe; Yoshifumi Ubara; Koki Mise; Toshiharu Ueno; Keiichi Sumida; Masayuki Yamanouchi; Noriko Hayami; Junichi Hoshino; Masahiro Kawada; Aya Imafuku; Rikako Hiramatsu; Eiko Hasegawa; Naoki Sawa; Kenmei Takaichi
Journal:  J Am Soc Nephrol       Date:  2015-11-30       Impact factor: 10.121

Review 5.  Renal artery embolization-indications, technical approaches and outcomes.

Authors:  Arnaud Muller; Olivier Rouvière
Journal:  Nat Rev Nephrol       Date:  2014-12-23       Impact factor: 28.314

6.  Transarterial renal embolization for enlarged horseshoe kidney.

Authors:  Akiko Fujisaki; Yoshifumi Ubara; Tatsuya Suwabe; Junichi Hoshino; Shohei Nakanishi; Masayuki Yamanouchi; Noriko Hayami; Eiko Hasegawa; Yuji Marui; Naoki Sawa; Fumi Takemoto; Kenmei Takaichi
Journal:  Clin Exp Nephrol       Date:  2009-12-15       Impact factor: 2.801

7.  Transcatheter arterial embolization using ethanol in a dialysis patient for contracting enlarged polycystic kidneys.

Authors:  Hark Rim; Gyoo-Sik Jung; Yeon Soon Jung
Journal:  Korean J Radiol       Date:  2010-08-27       Impact factor: 3.500

Review 8.  A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease.

Authors:  Niek F Casteleijn; Folkert W Visser; Joost P H Drenth; Tom J G Gevers; Gerbrand J Groen; Marie C Hogan; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2014-09       Impact factor: 5.992

Review 9.  Cyst infection in autosomal dominant polycystic kidney disease: our experience at Toranomon Hospital and future issues.

Authors:  Tatsuya Suwabe
Journal:  Clin Exp Nephrol       Date:  2020-07-22       Impact factor: 2.801

10.  Transperitoneal laparoscopic nephrectomy for autosomal dominant polycystic kidney disease.

Authors:  Grégory Verhoest; Arnaud Delreux; Romain Mathieu; Jean-Jacques Patard; Cécile Vigneau; Nathalie Rioux-Leclercq; Karim Bensalah
Journal:  JSLS       Date:  2012 Jul-Sep       Impact factor: 2.172

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.